12/08/2025
In this interview, we break down why low-dose atropine, not FDA-approved, has become one of the most important discussions in myopia control this year. Dr. Jennifer Lyerly and Dr. Daryl Glover sit with myopia expert Dr. Ashley Wallace-Tucker to analyze the STAR Study, the FDA’s request for additional data, and what this means for clinicians prescribing low-dose atropine off-label.
Dr. Lyerly also reviews landmark atropine studies — including ATOM, LAMP, and LAMP-II — that have shaped the global understanding of atropine’s effectiveness in slowing myopia progression. These foundational studies are contrasted with the STAR Study to help clinicians understand why results differed and what matters most in practice today